Literature DB >> 2249668

HIV-1 tat protein stimulates transcription by binding to a U-rich bulge in the stem of the TAR RNA structure.

C Dingwall1, I Ernberg, M J Gait, S M Green, S Heaphy, J Karn, A D Lowe, M Singh, M A Skinner.   

Abstract

The HIV-1 trans-activator protein, tat, is an RNA binding protein with a high affinity for a U-rich bulge near the tip of the stem in the RNA stem-loop structure encoded by the trans-activation responsive region (TAR). A Scatchard analysis of tat binding has shown that the purified protein forms a one-to-one complex with HIV-1 TAR RNA with a dissociation constant of Kd = 12 nM. Deletion of the uridine residues in the bulge or substitution with guanine residues produced RNAs with a 6- to 8-fold lower affinity than wild-type TAR. Introduction of a point mutation expected to destabilize base pairing in nearby residues of the TAR stem-loop structure reduced tat binding 10-fold. In contrast, mutations that alter the sequence of the six nucleotide long loop at the tip of TAR RNA structure, and mutations which alter the sequence of the stem whilst preserving Watson-Crick base pairing, do not affect tat binding significantly. There is a direct correlation between the ability of tat to bind to TAR RNA and to activate HIV transcription. Viral LTRs carrying TAR sequences encoding any of the mutations known to produce transcripts which bind tat weakly, are not stimulated efficiently by tat in vivo.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2249668      PMCID: PMC552188          DOI: 10.1002/j.1460-2075.1990.tb07637.x

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  47 in total

1.  RNA bulges and the helical periodicity of double-stranded RNA.

Authors:  A Bhattacharyya; A I Murchie; D M Lilley
Journal:  Nature       Date:  1990-02-01       Impact factor: 49.962

2.  An antitermination protein engages the elongating transcription apparatus at a promoter-proximal recognition site.

Authors:  S Barik; B Ghosh; W Whalen; D Lazinski; A Das
Journal:  Cell       Date:  1987-09-11       Impact factor: 41.582

3.  Anti-termination of transcription within the long terminal repeat of HIV-1 by tat gene product.

Authors:  S Y Kao; A F Calman; P A Luciw; B M Peterlin
Journal:  Nature       Date:  1987 Dec 3-9       Impact factor: 49.962

4.  Elevated levels of mRNA can account for the trans-activation of human immunodeficiency virus.

Authors:  B M Peterlin; P A Luciw; P J Barr; M D Walker
Journal:  Proc Natl Acad Sci U S A       Date:  1986-12       Impact factor: 11.205

5.  Lac repressor binding to non-operator DNA: detailed studies and a comparison of eequilibrium and rate competition methods.

Authors:  S Y Lin; A D Riggs
Journal:  J Mol Biol       Date:  1972-12-30       Impact factor: 5.469

6.  Genome organization and transactivation of the human immunodeficiency virus type 2.

Authors:  M Guyader; M Emerman; P Sonigo; F Clavel; L Montagnier; M Alizon
Journal:  Nature       Date:  1987 Apr 16-22       Impact factor: 49.962

7.  Disulfide-bond cleavage and formation in proteins.

Authors:  O Smithies
Journal:  Science       Date:  1965-12-17       Impact factor: 47.728

8.  Trans-activation of human immunodeficiency virus gene expression is mediated by nuclear events.

Authors:  J Hauber; A Perkins; E P Heimer; B R Cullen
Journal:  Proc Natl Acad Sci U S A       Date:  1987-09       Impact factor: 11.205

9.  Recombinant genomes which express chloramphenicol acetyltransferase in mammalian cells.

Authors:  C M Gorman; L F Moffat; B H Howard
Journal:  Mol Cell Biol       Date:  1982-09       Impact factor: 4.272

10.  The specificity of the human immunodeficiency virus type 2 transactivator is different from that of human immunodeficiency virus type 1.

Authors:  M Emerman; M Guyader; L Montagnier; D Baltimore; M A Muesing
Journal:  EMBO J       Date:  1987-12-01       Impact factor: 11.598

View more
  161 in total

Review 1.  Relationships between proteasomes and viral gene products.

Authors:  A S Jarrousse; K Gautier; S Apcher; S Badaoui; G Boissonnet; M H Dadet; L Henry; J P Bureau; H P Schmid; F Petit
Journal:  Mol Biol Rep       Date:  1999-04       Impact factor: 2.316

2.  Straightening of bulged RNA by the double-stranded RNA-binding domain from the protein kinase PKR.

Authors:  X Zheng; P C Bevilacqua
Journal:  Proc Natl Acad Sci U S A       Date:  2000-12-19       Impact factor: 11.205

3.  Role for human immunodeficiency virus type 1 Tat protein in suppression of viral reverse transcriptase activity during late stages of viral replication.

Authors:  M Kameoka; L Rong; M Götte; C Liang; R S Russell; M A Wainberg
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

4.  Identification of ligands for RNA targets via structure-based virtual screening: HIV-1 TAR.

Authors:  A V Filikov; V Mohan; T A Vickers; R H Griffey; P D Cook; R A Abagyan; T L James
Journal:  J Comput Aided Mol Des       Date:  2000-08       Impact factor: 3.686

5.  Two crystal forms of helix II of Xenopus laevis 5S rRNA with a cytosine bulge.

Authors:  Y Xiong; M Sundaralingam
Journal:  RNA       Date:  2000-09       Impact factor: 4.942

6.  Tat is required for efficient HIV-1 reverse transcription.

Authors:  D Harrich; C Ulich; L F García-Martínez; R B Gaynor
Journal:  EMBO J       Date:  1997-03-17       Impact factor: 11.598

7.  Repression of the HIV-1 5' LTR promoter and inhibition of HIV-1 replication by using engineered zinc-finger transcription factors.

Authors:  Lindsey Reynolds; Christopher Ullman; Michael Moore; Mark Isalan; Michelle J West; Paul Clapham; Aaron Klug; Yen Choo
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-06       Impact factor: 11.205

Review 8.  Mechanism of action of regulatory proteins encoded by complex retroviruses.

Authors:  B R Cullen
Journal:  Microbiol Rev       Date:  1992-09

9.  An adenosine at position 27 in the human immunodeficiency virus type 1 trans-activation response element is not critical for transcriptional or translational activation by Tat.

Authors:  A D Blanchard; R Powell; M Braddock; A J Kingsman; S M Kingsman
Journal:  J Virol       Date:  1992-11       Impact factor: 5.103

10.  Inhibition of human immunodeficiency virus type 1 tat-trans-activation-responsive region interaction by an antiviral quinolone derivative.

Authors:  Sara Richter; Cristina Parolin; Barbara Gatto; Claudia Del Vecchio; Egidio Brocca-Cofano; Arnaldo Fravolini; Giorgio Palù; Manlio Palumbo
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.